



Claims


1. A compound having the formula




- 5 a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof; wherein
- G is a direct bond or C₁₋₁₀alkanediyl optionally substituted with one or more substituents individually selected from the group of substituents consisting of hydroxy, C₁₋₆alkyloxy, Ar¹C₁₋₆alkyloxy, C₁₋₆alkylthio, Ar¹C₁₋₆alkylthio,
- 10 HO(-CH₂-CH₂-O)_n, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n or Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n;
- R¹ is Ar¹ or a monocyclic or bicyclic heterocycle being selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydrofuranlyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl,
- 15 isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranlyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1*H*-imidazo[4,5-*b*]pyridinyl, 3*H*-imidazo[4,5-*b*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridyl or a radical of formula




(c-1)




(c-2)




(c-3)



(c-4)




(c-5)




(c-6)

20



(c-7)



(c-8)

;

- wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted with 1 or where possible more, such as 2, 3, 4 or 5, substituents individually selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)amino, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{5c}-, Ar¹-SO₂-NR^{5c}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{5c}R^{5d}, HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono- or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-;
- each n independently is 1, 2, 3 or 4;
 each m independently is 1 or 2;
 each p independently is 1 or 2;
 each t independently is 0, 1 or 2;
 Q is R⁷, pyrrolidinyl substituted with R⁷, piperidinyl substituted with R⁷ or homo-piperidinyl substituted with R⁷ wherein
 R⁷ is C₁₋₆alkyl substituted with a heterocycle or R⁷ is C₁₋₆alkyl substituted with both a radical -OR⁸ and a heterocycle, wherein said heterocycle is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine; wherein each of said heterocycle may be optionally substituted with one or two substituents selected from the group consisting of C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, hydroxy, carboxyl, C₁₋₄alkyloxycarbonyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₄alkylcarbonylamino, aminosulfonyl and mono- or di(C₁₋₄alkyl)aminosulfonyl;
 R⁸ is hydrogen, C₁₋₆alkyl or Ar¹C₁₋₆alkyl;
 one of R^{2a} and R^{3a} is selected from halo, optionally mono- or polysubstituted C₁₋₆alkyl, optionally mono- or polysubstituted C₂₋₆alkenyl, nitro, hydroxy, Ar², N(R^{4a}R^{4b}), N(R^{4a}R^{4b})sulfonyl, N(R^{4a}R^{4b})carbonyl, C₁₋₆alkyloxy, Ar²oxy, Ar²C₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, or -C(=Z)Ar²; and the other one of R^{2a} and R^{3a} is hydrogen;
 wherein
 - =Z is =O, =CH-C(=O)-NR^{5a}R^{5b}, =CH₂, =CH-C₁₋₆alkyl, =N-OH or =N-O-C₁₋₆alkyl; and
 - the optional substituents on C₁₋₆alkyl and C₂₋₆alkenyl can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydroxy, cyano, halo, nitro, N(R^{4a}R^{4b}), N(R^{4a}R^{4b})sulfonyl, Het, Ar², C₁₋₆alkyloxy, C₁₋₆alkyl-S(=O)₀, Ar²oxy,

$\text{Ar}^2\text{-S(=O)}_t$, $\text{Ar}^2\text{C}_{1-6}\text{alkyloxy}$, $\text{Ar}^2\text{C}_{1-6}\text{alkyl-S(=O)}_t$, Het-oxy , Het-S(=O)_t ,
 $\text{HetC}_{1-6}\text{alkyloxy}$, $\text{HetC}_{1-6}\text{alkyl-S(=O)}_t$, carboxyl, $\text{C}_{1-6}\text{alkyloxycarbonyl}$ and
 -C(=Z)Ar^2 ;

in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, $\text{C}_{1-6}\text{alkyl}$ or halogen and

5 R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, $\text{C}_{1-6}\text{alkyl}$ or halogen and
 R^{2b} is hydrogen;

R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each
independently selected from the group of substituents consisting of hydrogen,

10 $\text{C}_{1-6}\text{alkyl}$, $\text{Ar}^2\text{C}_{1-6}\text{alkyl}$, $(\text{Ar}^2)(\text{hydroxy})\text{C}_{1-6}\text{alkyl}$, $\text{Het-C}_{1-6}\text{alkyl}$, $\text{hydroxC}_{1-6}\text{alkyl}$,
mono- and di- $(\text{C}_{1-6}\text{alkyloxy})\text{C}_{1-6}\text{alkyl}$, $(\text{hydroxC}_{1-6}\text{alkyl})\text{oxyC}_{1-6}\text{alkyl}$,

$\text{Ar}^1\text{C}_{1-6}\text{alkyloxy-C}_{1-6}\text{alkyl}$, $\text{dihydroxC}_{1-6}\text{alkyl}$, $(\text{C}_{1-6}\text{alkyloxy})(\text{hydroxy})\text{C}_{1-6}\text{alkyl}$,
 $(\text{Ar}^1\text{C}_{1-6}\text{alkyloxy})(\text{hydroxy})\text{C}_{1-6}\text{alkyl}$, $\text{Ar}^1\text{oxy-C}_{1-6}\text{alkyl}$, $(\text{Ar}^1\text{oxy})(\text{hydroxy})\text{-}$
 $\text{C}_{1-6}\text{alkyl}$, $\text{aminoC}_{1-6}\text{alkyl}$, mono- and di $(\text{C}_{1-6}\text{alkyl})\text{amino-C}_{1-6}\text{alkyl}$,

15 $\text{carboxylC}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkyloxycarbonylC}_{1-6}\text{alkyl}$, $\text{aminocarbonylC}_{1-6}\text{alkyl}$, mono-
and di $(\text{C}_{1-6}\text{alkyl})\text{aminocarbonylC}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylcarbonylC}_{1-6}\text{alkyl}$, $(\text{C}_{1-4}\text{alkyl-}$
 $\text{oxy})_2\text{P(=O)-C}_{1-6}\text{alkyl}$, $(\text{C}_{1-4}\text{alkyloxy})_2\text{P(=O)-O-C}_{1-6}\text{alkyl}$, aminosulfonyl-
 $\text{C}_{1-6}\text{alkyl}$, mono- and di $(\text{C}_{1-6}\text{alkyl})\text{aminosulfonyl-C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkylcarbonyl}$,

20 $\text{Ar}^2\text{carbonyl}$, Het-carbonyl , $\text{Ar}^2\text{C}_{1-6}\text{alkylcarbonyl}$, $\text{Het-C}_{1-6}\text{alkylcarbonyl}$,
 $\text{C}_{1-6}\text{alkylsulfonyl}$, aminosulfonyl , mono- and di $(\text{C}_{1-6}\text{alkyl})\text{aminosulfonyl}$,
 $\text{Ar}^2\text{sulfonyl}$, $\text{Ar}^2\text{C}_{1-6}\text{alkylsulfonyl}$, Ar^2 , Het , Het-sulfonyl , $\text{HetC}_{1-6}\text{alkylsulfonyl}$;

R^5 is hydrogen or $\text{C}_{1-6}\text{alkyl}$;

R^{5a} and R^{5b} can be the same or can be different relative to one another, and are each
independently hydrogen or $\text{C}_{1-6}\text{alkyl}$; or

25 R^{5a} and R^{5b} taken together may form a bivalent radical of formula $\text{-(CH}_2\text{)}_s\text{-}$ wherein s is 4
or 5;

R^{5c} and R^{5d} can be the same or can be different relative to one another, and are each
independently hydrogen or $\text{C}_{1-6}\text{alkyl}$; or


30 R^{5c} and R^{5d} taken together may form a bivalent radical of formula $\text{-(CH}_2\text{)}_s\text{-}$ wherein s is 4
or 5;

Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents
selected from halo, hydroxy, $\text{C}_{1-6}\text{alkyl}$, $\text{hydroxC}_{1-6}\text{alkyl}$, $\text{polyhaloC}_{1-6}\text{alkyl}$, and
 $\text{C}_{1-6}\text{alkyloxy}$;

35 Ar^2 is phenyl, phenyl annelated with $\text{C}_{5-7}\text{cycloalkyl}$, or phenyl substituted with 1 or
more, such as 2, 3, 4 or 5, substituents selected from halo, cyano, $\text{C}_{1-6}\text{alkyl}$,
 $\text{Het-C}_{1-6}\text{alkyl}$, $\text{Ar}^1\text{-C}_{1-6}\text{alkyl}$, $\text{cyanoC}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{cyanoC}_{2-6}\text{alkenyl}$,
 $\text{R}^{6b}\text{-O-C}_{3-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{cyanoC}_{2-6}\text{alkynyl}$, $\text{R}^{6b}\text{-O-C}_{3-6}\text{alkynyl}$, Ar^1 , Het ,
 $\text{R}^{6b}\text{-O-}$, $\text{R}^{6b}\text{-S-}$, $\text{R}^{6c}\text{-SO-}$, $\text{R}^{6c}\text{-SO}_2\text{-}$, $\text{R}^{6b}\text{-O-C}_{1-6}\text{alkyl-SO}_2\text{-}$, $\text{-N(R}^{6a}\text{R}^{6b})\text{-}$, polyhalo-

- C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy, polyhalo C_{1-6} alkylthio, $R^{6c}-C(=O)-$,
 $R^{6b}-O-C(=O)-$, $N(R^{6a}R^{6b})-C(=O)-$, $R^{6b}-O-C_{1-10}$ alkyl, $R^{6b}-S-C_{1-6}$ alkyl,
 $R^{6c}-S(=O)_2-C_{1-6}$ alkyl, $N(R^{6a}R^{6b})-C_{1-6}$ alkyl, $R^{6c}-C(=O)-C_{1-6}$ alkyl,
 $R^{6b}-O-C(=O)-C_{1-6}$ alkyl, $N(R^{6a}R^{6b})-C(=O)-C_{1-6}$ alkyl, $R^{6c}-C(=O)-NR^{6b}-$,
 5 $R^{6c}-C(=O)-O-$, $R^{6c}-C(=O)-NR^{6b}-C_{1-6}$ alkyl, $R^{6c}-C(=O)-O-C_{1-6}$ alkyl,
 $N(R^{6a}R^{6b})-S(=O)_2-$, $H_2N-C(=NH)-$;
 R^{6a} is hydrogen, C_{1-6} alkyl, Ar^1 , Ar^1C_{1-6} alkyl, C_{1-6} alkylcarbonyl, Ar^1 carbonyl,
 Ar^1C_{1-6} alkylcarbonyl, C_{1-6} alkylsulfonyl, Ar^1 sulfonyl, Ar^1C_{1-6} alkylsulfonyl,
 C_{1-6} alkyloxy C_{1-6} alkyl, amino C_{1-6} alkyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkyl,
 10 hydroxy C_{1-6} alkyl, (carboxyl)- C_{1-6} alkyl, (C_{1-6} alkyloxycarbonyl)- C_{1-6} alkyl,
 aminocarbonyl C_{1-6} alkyl, mono- and di(C_{1-6} alkyl)aminocarbonyl C_{1-6} alkyl,
 aminosulfonyl- C_{1-6} alkyl, mono- and di(C_{1-6} alkyl)aminosulfonyl- C_{1-6} alkyl, Het,
 Het- C_{1-6} alkyl, Het-carbonyl, Het-sulfonyl, Het- C_{1-6} alkylcarbonyl;
 R^{6b} is hydrogen, C_{1-6} alkyl, Ar^1 or Ar^1C_{1-6} alkyl;
 15 R^{6c} is C_{1-6} alkyl, Ar^1 or Ar^1C_{1-6} alkyl;
 Het is a heterocycle being selected from tetrahydrofuranyl, tetrahydrothienyl,
 pyrrolidinyl, pyrrolidinonyl, furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl,
 imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl,
 piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, pyridyl, pyrazinyl,
 20 pyridazinyl, pyrimidinyl, tetrahydroquinolinyl, quinolinyl, isoquinolinyl,
 benzodioxanyl, benzodioxolyl, indolinyl, indolyl, each of said heterocycle may
 optionally be substituted with oxo, amino, Ar^1 , C_{1-4} alkyl, amino C_{1-4} alkyl,
 Ar^1C_{1-4} alkyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkyl, mono- or di(C_{1-6} alkyl)amino,
 (hydroxy C_{1-6} alkyl)amino, and optionally further with one or two C_{1-4} alkyl
 25 radicals.


2. A compound according to claim 1 wherein the compound has the formula:



- wherein R^5 , G , R^1 , R^{2a} , R^{2b} , R^{3a} , R^{3b} are as claimed in claim 1 and
 30 Alk^1 is C_{1-6} alkanediyl;
 R^{7a} is a heterocycle which is selected from the group consisting of oxazolidine,
 thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl,
 thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydro-
 oxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and


1,1-dioxohexahydrothiazepine; wherein each of said heterocycle may be optionally substituted with one or two substituents selected from the group consisting of C₁₋₆alkyl, hydroxy, carboxyl, C₁₋₄alkyloxycarbonyl, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₄alkylcarbonylamino, aminosulfonyl and mono- or di(C₁₋₄alkyl)aminosulfonyl.

3. A compound according to claim 1 wherein the compound has the formula:




wherein R⁵, G, R¹, R^{2a}, R^{2b}, R^{3a}, R^{3b} are as claimed in claim 1 and Alk¹ and R^{7a} are as claimed in claim 2.

4. A compound according to claim 1 wherein the compound has the formula:



wherein R⁵, G, R¹, R^{2a}, R^{2b}, R^{3a}, R^{3b} are as claimed in claim 1, and Alk¹ and R^{7a} are as claimed in claim 2.

5. A compound according to claim 1 wherein the compound has the formula:




wherein R⁵, G, R¹, R^{3b}, R^{4a} are as claimed in claim 1, and Alk¹ and R^{7a} are as claimed in claim 2; and

R⁹, R¹⁰, R¹¹ each independently are selected from halo, cyano, C₁₋₆alkyl, Het-C₁₋₆alkyl, Ar¹-C₁₋₆alkyl, cyanoC₁₋₆alkyl, C₂₋₆alkenyl, cyanoC₂₋₆alkenyl,


R^{6b} -O-C₃₋₆alkenyl, C₂₋₆alkynyl, cyanoC₂₋₆alkynyl, R^{6b} -O-C₃₋₆alkynyl, Ar¹,
 Het, R^{6b} -O-, R^{6b} -S-, R^{6c} -SO-, R^{6c} -SO₂-, R^{6b} -O-C₁₋₆alkyl-SO₂-, N(R^{6a} R^{6b}),
 polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, polyhaloC₁₋₆alkylthio, R^{6c} -C(=O)-,
 R^{6b} -O-C(=O)-, N(R^{6a} R^{6b})-C(=O)-, R^{6b} -O-C₁₋₆alkyl, R^{6b} -S-C₁₋₆alkyl,
 R^{6c} -S(=O)₂-C₁₋₆alkyl, N(R^{6a} R^{6b})-C₁₋₆alkyl, R^{6c} -C(=O)-C₁₋₆alkyl,
 R^{6b} -O-C(=O)-C₁₋₆alkyl, N(R^{6a} R^{6b})-C(=O)-C₁₋₆alkyl, R^{6c} -C(=O)-NR^{6b}-,
 R^{6c} -C(=O)-O-, R^{6c} -C(=O)-NR^{6b}-C₁₋₆alkyl, R^{6c} -C(=O)-O-C₁₋₆alkyl,
 N(R^{6a} R^{6b})-S(=O)₂-, H₂N-C(=NH)-;
 and Alk is C₁₋₆alkanediyl.

6. A compound according to claim 1 wherein the compound has the formula:



wherein R^5 , G, R^1 , R^{4a} , R^{2b} are as claimed in claim 1, and Alk¹ and R^{7a} are as
 claimed in claim 2; R^9 , R^{10} , R^{11} and Alk are as claimed in claim 5.


7. A compound according to claim 1 wherein the compound has the formula:



wherein R^5 , G, R^1 , R^{3b} are as claimed in claim 1, and Alk¹ and R^{7a} are as claimed
 in claim 2; R^9 , R^{10} and Alk are as claimed in claim 5; and

R^{6a} is hydrogen, C₁₋₆alkyl, Ar¹, Ar¹C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹carbonyl,
 Ar¹C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, Ar¹sulfonyl, Ar¹C₁₋₆alkylsulfonyl,
 C₁₋₆alkyloxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl,
 hydroxyC₁₋₆alkyl, (carboxyl)-C₁₋₆alkyl, (C₁₋₆alkyloxycarbonyl)-C₁₋₆alkyl,
 aminocarbonylC₁₋₆alkyl, mono- and di(C₁₋₆alkyl)aminocarbonylC₁₋₆alkyl,
 aminosulfonyl-C₁₋₆alkyl, mono- and di(C₁₋₆alkyl)aminosulfonyl-C₁₋₆alkyl,
 Het, Het-C₁₋₆alkyl, Het-carbonyl, Het-sulfonyl, Het-C₁₋₆alkylcarbonyl;
 R^{6b} is hydrogen, C₁₋₆alkyl, Ar¹ or Ar¹C₁₋₆alkyl.


8. A compound according to claim 1 wherein the compound has the formula:




5

wherein R^5 , G , R^1 , R^{2b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2; R^9 , R^{10} and Alk are as claimed in claim 5; and R^{6a} and R^{6b} are as claimed in claim 7.

- 10 9. A compound according to claim 1 wherein the compound has the formula:



or of formula:



15


wherein R^5 , G , R^1 , R^{2a} , R^{2b} , R^{3a} , R^{3b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2.

- 20 10. A compound according to any of claims 2 to 10, wherein R^{7a} is a heterocycle selected from the group consisting of oxazolidine, thiazolidine, morpholinyl, thiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine; wherein each of said heterocycle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6} alkyl, hydroxy C_{1-6} alkyl, aminocarbonyl C_{1-6} alkyl.

11. A compound according to any of claims 2 to 10, wherein R^{7a} is a heterocycle, wherein said heterocycle is oxazolidine, thiazolidine, morpholinyl or thiomorpholinyl, wherein each of said heterocycle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6} alkyl, hydroxy- C_{1-6} alkyl, aminocarbonyl C_{1-6} alkyl.
12. A compound according to any of claims 2 to 10, wherein R^{7a} is morpholinyl.
13. A compound according to any of claims 5 to 8, wherein Alk is methylene.
14. A compound according to any of claims 2 to 10, wherein Alk^1 is C_{1-4} alkanediyl.
15. A compound according to any of claims 5 to 8, wherein R^9 , R^{10} , R^{11} are selected from halo, cyano, C_{1-6} alkyl, Het- C_{1-6} alkyl, Ar^1 - C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{2-6} alkenyl, cyano C_{2-6} alkenyl, R^{6b} -O- C_{3-6} alkenyl, C_{2-6} alkynyl, cyano C_{2-6} alkynyl, R^{6b} -O- C_{3-6} alkynyl, Ar^1 , Het, R^{6b} -O-, R^{6b} -S-, R^{6c} -SO-, R^{6c} -SO₂-, R^{6b} -O- C_{1-6} alkyl-SO₂-, -N($R^{6a}R^{6b}$), CF₃, R^{6c} -C(=O)-, R^{6b} -O-C(=O)-, N($R^{6a}R^{6b}$)-C(=O)-, R^{6b} -O- C_{1-6} alkyl, R^{6b} -S- C_{1-6} alkyl, R^{6c} -S(=O)₂- C_{1-6} alkyl, N($R^{6a}R^{6b}$)- C_{1-6} alkyl, R^{6c} -C(=O)- C_{1-6} alkyl, R^{6b} -O-C(=O)- C_{1-6} alkyl, N($R^{6a}R^{6b}$)-C(=O)- C_{1-6} alkyl and R^{6c} -C(=O)-NR^{6b}-, H₂N-C(=NH)-.
16. A compound according to any of claims 5 to 8, wherein R^9 , R^{10} , R^{11} are selected from C_{1-6} alkyl, Het- C_{1-6} alkyl, Ar^1 - C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{2-6} alkenyl, cyano- C_{2-6} alkenyl, R^{6b} -O- C_{3-6} alkenyl, C_{2-6} alkynyl, cyano C_{2-6} alkynyl, R^{6b} -O- C_{3-6} alkynyl, R^{6b} -O- C_{1-6} alkyl, R^{6b} -S- C_{1-6} alkyl, R^{6c} -S(=O)₂- C_{1-6} alkyl, N($R^{6a}R^{6b}$)- C_{1-6} alkyl, R^{6b} -O-C(=O)- C_{1-6} alkyl and N($R^{6a}R^{6b}$)-C(=O)- C_{1-6} alkyl;
17. A compound according to any of claims 5 to 8, wherein R^9 , R^{10} , R^{11} are selected from C_{1-6} alkyl, Het- C_{1-6} alkyl, Ar^1 - C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{2-6} alkenyl, cyano- C_{2-6} alkenyl, C_{2-6} alkynyl, cyano C_{2-6} alkynyl, R^{6b} -O- C_{1-6} alkyl, amino-S(=O)₂- C_{1-6} alkyl, R^{6b} -O-C(=O)- C_{1-6} alkyl, amino-C(=O)- C_{1-6} alkyl, mono- and diamino-C(=O)- C_{1-6} alkyl;
18. A compound according to any of claims 5 to 8, wherein R^9 , R^{10} , R^{11} are C_{1-6} alkyl or R^{6b} -O- C_{1-6} alkyl; and R^{10} and/or R^{11} may also be hydrogen.
19. A compound according to any of claims 1 to 18, wherein G is C_{1-10} alkanediyl.

20. A compound according to any of claims 1 to 18, wherein G is methylene.

21. A compound according to any of claims 1 to 19 wherein R¹ is Ar¹, quinolinyl,
5 benzimidazolyl, a radical of formula



pyrazinyl, or pyridyl; or wherein Ar¹, quinolinyl, benzimidazolyl, a radical of
formula (c-4) may be substituted with 1 or where possible with 2 or 3 substituents
independently selected from the group consisting of halo, hydroxy, amino, cyano,
10 carboxyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, Ar¹,
Ar¹C₁₋₆alkyl, Ar¹C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)amino,
mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino,
C₁₋₆alkyl-SO₂-NR^{5c}-, Ar¹-SO₂-NR^{5c}-, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{5c}R^{5d},
HO(-CH₂-CH₂-O)_n-, halo(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-,
15 Ar¹C₁₋₆alkyloxy(-CH₂-CH₂-O)_n- and mono- or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n-;
wherein each n independently is 1, 2, 3 or 4; each m independently is 1 or 2; Ar¹,
R^{5c}, R^{5d} are as claimed in claim 1.


22. A compound according to any of claims 1 to 20 wherein R¹ is Ar¹, quinolinyl,
20 benzimidazolyl or a radical of formula (c-4) wherein m is 2, pyrazinyl, or pyridyl,
wherein each of these radicals may optionally be substituted with one, two or three
radicals selected from the group consisting of halo, hydroxy, C₁₋₆alkyl,
C₁₋₆alkyloxy, Ar¹C₁₋₆alkyloxy, (C₁₋₆alkyloxy)C₁₋₆alkyloxy.

23. A compound according to any of claims 1 to 20 wherein R¹ is phenyl optionally
substituted with one, two or three radicals selected from the group consisting of
halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy; quinolinyl; a radical (c-4) wherein m is 2,
optionally substituted with up to two radicals selected from C₁₋₆alkyl;
benzimidazolyl optionally substituted with C₁₋₆alkyl; pyridyl optionally substituted
30 with one or two radicals selected from hydroxy, halo, C₁₋₆alkyl, benzyloxy and
C₁₋₆alkyloxy, pyrazinyl optionally substituted with up to three radicals selected
from C₁₋₆alkyl; or pyridyl substituted or optionally substituted with one or two
radicals selected from the group consisting of halo, hydroxy, C₁₋₆alkyl,
C₁₋₆alkyloxy, Ar¹C₁₋₆alkyloxy, (C₁₋₆alkyloxy)C₁₋₆alkyloxy.


35

24. A compound according to any of claims 1 to 20 wherein R¹ is pyridyl optionally substituted with one or two radicals selected from hydroxy, halo, C₁₋₆alkyl, benzyloxy and C₁₋₆alkyloxy,
- 5 25. A compound according to any of claims 1 to 20 wherein R¹ is pyridyl optionally substituted with one or two radicals selected from hydroxy and C₁₋₆alkyl. C₁₋₆alkyloxy,
- 10 25. A compound according to any of claims 1 to 25, wherein, where applicable, one of R^{2a} and R^{3a} is selected from -N(R^{4a}R^{4b}), (R^{4a}R^{4b})N-CO-, C₁₋₆alkyl substituted with one or two substituents selected from hydroxy, cyano, Ar², Het or -N(R^{4a}R^{4b}) and C₂₋₆alkenyl substituted with cyano or Ar²; and the other one of R^{2a} and R^{3a} is hydrogen; and
- 15 in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, C₁₋₆alkyl or halogen and R^{3b} is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C₁₋₆alkyl or halogen and R^{2b} is hydrogen.
- 20 26. A compound according to any of claims 1 to 25, wherein, where applicable, one of R^{2a} and R^{3a} is selected from (R^{4a}R^{4b})N-CO-; C₁₋₆alkyl optionally substituted with hydroxy, Ar², Het or -N(R^{4a}R^{4b}); and C₂₋₆alkenyl substituted with Ar¹; and the other one of R^{2a} and R^{3a} is hydrogen; or
- 25 in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C₁₋₆alkyl and R^{3b} is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C₁₋₆alkyl and R^{2b} is hydrogen; Ar², Het, R^{4a} and R^{4b} are as in the definitions of the compounds of formula (I) or as in any subgroup specified herein.
- 30 27. A compound according to any of claims 25 or 26, wherein, where applicable, R^{2b} and R^{3b} are both hydrogen.
- 35 28. A compound according to claim 1, wherein the compound is 2-[6-{[2-(3-hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol.
29. A compound as claimed in any one of claims 1 to 28 for use as a medicine.


30. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 28.
- 5 31. The use of a compound as claimed in any of claims 1 to 28 for the manufacture of a medicament for inhibiting RSV.
32. A process for preparing a compound as claimed in any of claims 1 to 28, said process comprising
- 10 (a) reacting an intermediate of formula (II) with a reagent (III) as in the following reaction scheme:



- (b) reducing a compound (I-1-a) or (I-1-b) to obtain a compound (I-2-a) or (I-2-b) and subsequently oxidizing the alcohol group in (I-2-a) or (I-2-b) with a mild oxidant to obtain an intermediate (I-3-a) or (I-3-b) and subsequently alkylating (I-3-a) or (I-3-b) to obtain (I-4-a) or (I-4-b), which is further alkylated to obtain (I-5-a) or (I-5-b) as in the following reaction schemes wherein R^{12} is C_{1-6} alkyl wherein is R^{4a} and R^{4b} are as claimed in claims 1 to 28 but are other than hydrogen.
- 15
- 20





-135-





5

(c) converting the alcohol group in (I-2-a) or (I-2-b) to a leaving group and subsequently reacting the thus obtained products with an amine thus obtaining (I-6-a) or (I-6-b)

-136-






- 5 (d) converting an intermediate (I-3-a) or (I-3-b) to a compound (I-7-a) or (I-7-b) using a Wittig or Wittig-Horner procedure; selectively reducing the double bond in (I-7-a) or (I-7-b) thus obtaining compounds (I-8-a) or (I-8-b); reducing the cyano group in (I-9-a) or (I-9-b) to a methylene-amine group thus obtaining (I-10-a) or (I-10-b); mono- or dialkylating the latter thus obtaining compounds (I-11-a) or (I-11-b) ; or (I-12-a) or (I-12-b), wherein Alk¹ is C₄₋₆alkanediyl, R^{2a-1} is any of the substituents on alkenyl as defined in any of claims 1 – 28, and preferably R^{2a-1} is Ar² or CN:
- 10





15


-137-



5



-138-



5

10

and optionally converting the thus obtained compounds of formula (I) into their pharmaceutically acceptable base-addition or acid addition salt form by treatment with a suitable base or acid and conversely treating the base-addition or acid addition salt form with an acid or a base to obtain the free form of the compound of formula (I).